Form 4 for GTBP GT Biopharma, Inc.
Accepted 2022-07-19 00:00:00 ET · period of report 2022-07-15 · accession 0001493152-22-019876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-19 | 2022-07-15 | GTBP | Breen Michael Martin | Exec. COB, Interim CEO, Dir | A - Grant | $0.00 | +278.1K | 606.2K | +85% | $0 |
| D | 2022-07-19 | 2022-07-15 | GTBP | Breen Michael Martin | Exec. COB, Interim CEO, Dir | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-15 | A | A | 278,058 | $0.00 | 606,218 | D | — | — | |
| 2 | Derivative | Option to purchase Common Stock | 2022-07-15 | A | A | 50,000 | $0.00 | 50,000 | D | $2.48 · 2022-07-15 to 2032-07-14 | 50,000 Common Stock |